"Designing Growth Strategies is in our DNA"

U.S. Ophthalmic Disease Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, and Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration, Diabetic Retinopathy}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI108840

 


U.S. Ophthalmic Disease Therapeutics Market

  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Consulting Services
    How will you benefit from our consulting services ?